In conclusion, Sono@NAT10 blocks NAT10 phase‐separated condensates, reduces the acetylation level of SRSF2 protein, and reprograms macrophages from the M2 to M1 phenotype, thereby improving CRC immunotherapy efficacy (Graphic abstract). Here, SRSF2 is linked to colorectal carcinoma.